U.S. FDA Approves Supplemental New Drug Application For Expanded Indication Of Oxbryta® (voxelotor) For Children As Young As 4 Years Of Age With Sickle Cell Disease

By GlobeNewswire New dispersible tablet dosage form also approved Oxbryta is the first medicine that addresses the root cause of red blood cell sickling SOUTH SAN FRANCISCO, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (GBT) – Get Global Blood Therapeutics Inc Report today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of a supplemental New Drug Application (sNDA) for Oxbryta ® (voxelotor) tablets for the treatment of sickle cell disease (SCD) in children ages 4 to less than 12 years. This approval expands the previousl…

Read More